Daily PubMed evidence board
Efficacy and Moderators of Mindfulness-Based Cognitive Therapy in Difficult-to-Treat Depression: A Systematic Review and Individual Participant Data Meta-Analysis.
This pooled analysis combined individual participant data from randomized trials to see whether mindfulness-based cognitive therapy (MBCT) helps adults wh…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42284258Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This pooled analysis combined individual participant data from randomized trials to see whether mindfulness-based cognitive therapy (MBCT) helps adults whose depression has been hard to treat with usual care. Across seven studies (777 participants), MBCT reduced depressive symptoms more than usual care at the end of treatment and at medium-term follow-up. MBCT did not show clear advantage over other active psychosocial treatments. The authors did not find strong patient characteristics that changed the effect, suggesting benefits may apply across different levels of severity and chronicity. Full-text review is needed to check how big the benefit is in absolute terms, what side effects (if any) were reported, and how MBCT was delivered in each trial.
Why it matters
- Addresses efficacy of mindfulness-based cognitive therapy (MBCT) for adults with difficult-to-treat depression (DTD) - a group (treatment non-responders / treatment-resistant / chronic course) with high unmet need.
- Finds MBCT likely superior to treatment as usual (TAU) at post-treatment and medium-term follow-up, which could inform treatment selection and service planning for DTD.
- No evidence of superiority of MBCT over other active psychosocial interventions suggests MBCT may be one effective option among several, affecting prioritization decisions for resource allocation.
- Moderator analyses did not find robust predictors of response, implying effects may generalize across baseline severity, chronicity, and comorbidity - relevant for broad implementation considerations.
Primary outcomes
- Pooled effect on depressive symptom severity at post-treatment and medium-term follow-up; moderator analyses across baseline severity, chronicity, and comorbidity
Effect summary
Abstract reports MBCT likely superior to treatment as usual at post-treatment (SMD = -0.40; 95% CrI -0.64 to -0.16) and medium-term follow-up (SMD = -0.41; 95% CrI -0.76 to -0.02) with high posterior probabilities of surpassing a pre-specified minimal important difference; no evidence of superiority over other active psychosocial interventions; no robust moderators identified.
Benefit-cost lens
| Quick take | IPD meta-analysis suggests a moderate standardized benefit of MBCT versus TAU in DTD; cost-effectiveness and scale-up value depend on absolute benefit, local baseline outcomes, and implementation costs. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Summary based on abstract/IPD pooled standardized effect sizes; full-text needed to extract absolute outcomes, heterogeneity, adverse events, and resource use before any cost-benefit calculation. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based only on abstract and PubMed metadata. IPD meta-analyses generally improve bias handling, but risk depends on included trials' allocation concealment, blinding, handling of missing data, and selective reporting - details not available in abstract. Full-text review required for formal RoB assessment. |
Harms, equity, conflicts & implementation
| Implementation | Trained MBCT facilitators, group delivery infrastructure (or adapted formats), supervision and fidelity monitoring, referral pathways for DTD patients, and economic/resource planning; exact requirements depend on program model used in trials (details in full text). |
|---|---|
| Equity impact | Unclear from abstract. Equity implications depend on access to MBCT (trained facilitators, group-based delivery), cultural adaptation, and whether certain subgroups were underrepresented in the trials; full-text and trial-level demographics needed. |
| Harms | Abstract states MBCT appears to be a safe option, but specific adverse events or dropout patterns are not detailed; full-text required to characterize harms and trade-offs. |
| Replication | Unknown from abstract; replication across included trials likely, but independent replication and consistency across settings require full-text inspection. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.